BidaskClub upgraded shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) from a buy rating to a strong-buy rating in a research report released on Tuesday.

Other analysts have also recently issued research reports about the company. Zacks Investment Research raised Sucampo Pharmaceuticals from a hold rating to a buy rating and set a $11.00 price objective on the stock in a report on Tuesday, October 17th. UBS dropped their price objective on Sucampo Pharmaceuticals from $19.00 to $15.00 and set a buy rating on the stock in a report on Thursday, October 12th. Maxim Group set a $23.00 price objective on Sucampo Pharmaceuticals and gave the stock a buy rating in a report on Thursday, December 7th. B. Riley increased their price objective on Sucampo Pharmaceuticals from $14.00 to $18.00 and gave the stock a buy rating in a report on Wednesday, December 6th. Finally, ValuEngine raised Sucampo Pharmaceuticals from a hold rating to a buy rating in a report on Friday, December 1st. Two equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of $16.60.

Shares of Sucampo Pharmaceuticals (SCMP) traded up $0.25 on Tuesday, reaching $16.75. The company had a trading volume of 2,796,400 shares, compared to its average volume of 782,282. The stock has a market cap of $769.49, a PE ratio of 11.30, a price-to-earnings-growth ratio of 4.91 and a beta of 1.47. The company has a debt-to-equity ratio of 7.37, a current ratio of 5.11 and a quick ratio of 4.46. Sucampo Pharmaceuticals has a twelve month low of $9.30 and a twelve month high of $17.70.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.25 by $0.02. The business had revenue of $61.27 million for the quarter, compared to analysts’ expectations of $58.05 million. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The firm’s quarterly revenue was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.30 EPS. research analysts predict that Sucampo Pharmaceuticals will post 1.12 earnings per share for the current year.

In other Sucampo Pharmaceuticals news, insider Peter A. Kiener sold 50,000 shares of the firm’s stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $16.50, for a total value of $825,000.00. Following the sale, the insider now owns 52,023 shares of the company’s stock, valued at approximately $858,379.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 4.13% of the company’s stock.

Several institutional investors have recently made changes to their positions in SCMP. Vanguard Group Inc. increased its position in shares of Sucampo Pharmaceuticals by 48.9% during the 1st quarter. Vanguard Group Inc. now owns 1,456,787 shares of the biopharmaceutical company’s stock valued at $16,024,000 after purchasing an additional 478,226 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of Sucampo Pharmaceuticals by 2.3% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 180,303 shares of the biopharmaceutical company’s stock valued at $1,984,000 after purchasing an additional 4,104 shares during the last quarter. Capstone Asset Management Co. increased its position in shares of Sucampo Pharmaceuticals by 2.1% during the 2nd quarter. Capstone Asset Management Co. now owns 12,360 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 260 shares during the last quarter. Louisiana State Employees Retirement System increased its position in shares of Sucampo Pharmaceuticals by 1.0% during the 2nd quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 100 shares during the last quarter. Finally, Strs Ohio increased its position in shares of Sucampo Pharmaceuticals by 34.4% during the 2nd quarter. Strs Ohio now owns 60,900 shares of the biopharmaceutical company’s stock valued at $639,000 after purchasing an additional 15,600 shares during the last quarter. Hedge funds and other institutional investors own 65.31% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Sucampo Pharmaceuticals (SCMP) Raised to Strong-Buy at BidaskClub” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://www.watchlistnews.com/sucampo-pharmaceuticals-scmp-raised-to-strong-buy-at-bidaskclub/1766276.html.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.